24 February 2017
News and Views
Links and Services
This month's issue of the European Journal of Gastroenterology & Hepatology investigates whether weight-adjusted anti-tumor necrosis factor treatment favours obese patients with Crohn’s disease.
Adalimumab is a subcutaneous anti-tumor necrosis factor (anti-TNF) agent, effective in inducing a
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors